Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis

Eighteen patients affected by laparoscopically confirmed endometriosis were randomly assigned to three different schedules of treatment with gonadotropin-releasing hormone agonist (GnRH-a) (goserelin depot formulation 3.6 mg) every 28 days for 6 months. Six women received the first implant in early follicular phase, 4 in late luteal phase and 8 in 3rd and 17th day from onset of menses. Pretreatment and posttreatment laparoscopic score, performed according to the American Fertility Society scoring system, were compared; a significant reduction in the extent of disease was observed in each group investigated (A and C: p<0.01; B: p<0.05). In each treatment group after the second GnRH-a implant the mean levels of estrone-3-glucuronide (E1-3G), daily measured in early morning urine specimens during the control cycle and the first three months of therapy, were suppressed to menopausal women range. In group B during the 2nd and 3rd month of therapy, the urinary mean levels of EI-3G were significantly lower than in group A and C. In conclusion the different goserelin depot administration schedules gave similar laparoscopic improvement, in spite of the first GnRH-a administration in luteal phase allowed a more marked estrogenic suppression. Similar content being viewed by others

Buttram V.C. Jr, Reiter R.C., Ward S. Treatment of endometriosis with danazol: report of a 6-year prospective study. Fertil. Steril. 43: 353, 1985. Venturini P.L., Bertoiini S., Marré Brunenghi M.C., Daga A., Fasce V., Marcenaro A., Cimato M., De Cecco L. Endocrine, metabolic, and clinical effects of gestri-none in women with endometriosis. Fertil. Steril. 52: 589, 1989. Henzl M.R., Corson S.L., Moghissi K., Buttram V.C., Berqvist C, Jacobson J., For the nafarelin study group. Administration of nasal nafarelin as compared with oral danazol for endometriosis — A multicenter double-blind comparative clinical trial. N. Engl. J. Med. 318: 485, 1988. Henzl M.R., Kwei L. Efficacy and safety of nafarelin in the treatment of endometriosis. Am. J. Obstet. Gynecol. 162: 570, 1990. Meldrum D.R., Chang R.J., Lu J., Vale W., Rivier J., Judd H.L. ‘Medical oophorectomy’ using a long-acting GnRH agonist — A possible new approach to the treatment of endometriosis. J. Clin. Endocrinol. Metab. 54: 1081, 1982. Shaw R.W., Frase H.M., Boyle H. Intranasal LHRH in the treatment of women with endometriosis. Br. Med. J. 287: 1667, 1983. Dupont A., Dupont P., Belanger A., Mailoux J., Cusan L., Labrie F. Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing hormone (LH-RH) agonist [D-Trp6,des-Gly-NH2 10] LH-RH ethylamide. Fertil. Steril. 54: 227, 1990. Lemay A., Sandow J., Bureau M., Maheux R., Fontaine J.Y., Merat P. Prevention of follicular meturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in luteal phase. Fertil. Steril. 49: 410, 1988. Fraser H., Sandow J., Cowen G.M., Lumsden M.A., Haining R., Smith S.K. Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis. Fertil. Steril. 53: 61, 1990. Donnez J., Nisolle-Pochet M.F., Clerckx-Braun F., Sandow J., Casanas-Roux B.S. Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis. Fertil. Steril. 52: 27, 1989 Healy D.L., Lawson S.R., Abbot M., Baird D.T., Fraser H.M. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in luteal phase. J. Clin. Endocrinol. Metab. 63:619, 1986. Fraser H., Sandow J. Suppression of follicular maturation by infusion of luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey. J. Clin. Endocrinol. Metab. 60: 579, 1985. Ron-el R., Herman A., Golan A., Van der Ven H., Caspi E., Diedrich K. The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist. Fertil. Steril. 54: 233, 1990. The American Fertility Society Revised american fertility society classification of endometriosis: 1985. Fertil. Steril. 43: 351, 1985. Franssen A.M.H.W., Kauer M.H., Chadha D.R., Zijlastra J.A., Rolland R. Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin. Fertil. Steril. 51: 401, 1989. Pazzagli M., Magini A., Forti G., Bolelli G., Scarselli G., Noci I., Pellegri S., Rodbard D., Serio M. Measurement of 17ß estradiol and progesterone in diluted overnight urine. An approach to the study of luteal insufficiency. J. Steroid Biochem. 27: 399, 1987. Magini A., Pazzagli M., Salerno R., Simonis M., Mustacchi G., Serio M. Ovarian function in premenopausal women affected by breast cancer: the measurement of glucuronoconjugate metabolites of 17 beta estradiol and progesterone throughout one entire menstrual cycle. J. Steroid Biochem. 36: 523, 1990. Conn P.M., Crowley W.F. Gonadotropin-releasing hormone and its analogues. N. Engl. J. Med. 324: 93, 1990. Evers J.L.H. The second look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression. Fertil. Steril. 47: 502, 1987. West C.P., Lumsden M.A., Lawson S., Williamson J., Baird D.T. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil. Steril. 48: 45, 1987. Author information Authors and Affiliations Additional information Presented in part to: “Giornate Endocrinologiche Pisane”, May 10–11, 1991. Rights and permissions About this article Cite this article Magini, A., Pellegrini, S., Tavella, K. et al. Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis. J Endocrinol Invest 16, 775–780 (1993). https://doi.org/10.1007/BF03348925 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/BF03348925